Sales for the maker of O'Zampic have Slim Dan.

Live in the UK, this is the Marketplace Morning Report from the BBC World Service,

I'm Niana Byrne and a very good morning to you.

It's a blockbuster pharmaceutical company making some of the

most well-known drugs in the world. Nogo Nordisk is behind popular weight loss

and diabetes drugs like Ozempik and Wegovi. It's Europe's most valuable company with a market value of around half a trillion dollars.

But it didn't sell as many drugs as expected in the second quarter due to supply issues and more competition. I recently chatted with key

figures in this increasingly popular market starting with Patrick Johnson

Eli Lillie's president of diabetes and obesity. I think we inspire a novel and other inspires us.

Competition just makes us better and better every day. We're moving as quickly as we can, but there

are at times supply constraints in the market.

We think of it as a somewhat stable duopoly between Novo and Lily.

That's Emily Field, head of European Pharmaceuticals Equity Research at Barclays.

These two companies are the winners and everyone else is really scrambling for lack of a

better word to catch up.

Emily says she's seen a recent flurry of buyouts

in the pharmaceutical space.

It's Manon Chuckravarti.

I serve as the therapeutic global head

for cardiovascular renal and metabolism Product Development at Roche.

Dr. Tachovarti used to work for the California-based biotechnology company, Carmot Therapeutics,

until it was bought out in December by industry giant Roche.

...